Day: May 16, 2022

Posted on

Lors de la Journée internationale des familles, Angel Yeast encourage les ménages à cuisiner.

YICHANG, Chine, 16 mai 2022 /PRNewswire/ — Angel Yeast (en.angelyeast.com, SH600298), un fabricant international de levure et d’extraits de levure coté en bourse, a annoncé lors de la Journée internationale des familles (15 mai) la poursuite de son engagement de longue date à soutenir et promouvoir un mode de vie sain pour les familles du monde entier. En proposant une large gamme de produits à base de levure, l’entreprise entend inspirer et encourager les foyers urbains à cuisiner davantage.

International Day of Families, Angel Yeast encourages households to bake at home.

L’une des missions de la Journée internationale des familles étant de sensibiliser au bien-être des familles, Angel Yeast espère commencer par la gastronomie pour créer des discussions à l’échelle mondiale sur la manière d’avoir un mode de vie plus sain et plus durable, selon Xishan Wang, directeur général adjoint d’Angel Yeast.

« Ces dernières années, nous avons constaté que le nombre de gens qui cuisinent avait diminué. En effet, la vie moderne et l’ère numérique ont créé davantage d’options de restauration. Les jeunes, en particulier, n’ont pas envie de cuisiner, ce qui suscite des inquiétudes quant à la sécurité alimentaire, la nutrition, la pollution due aux emballages plastiques, ainsi qu’un manque de liens et d’ambiance familiale », a déclaré Wang.

Angel Yeast a joué un rôle de premier plan dans la consommation familiale de produits à base de levure en Chine. La société est progressivement devenue un fournisseur majeur sur le marché mondial. Les produits d’Angel Yeast sont utilisés par des millions de familles dans le monde dans la fabrication du pain, du naan, du baozi (petit pain farci à la vapeur) et de nombreuses autres pâtisseries.

Pour aider et encourager les gens à cuisiner des plats faits maison, Angel Yeast a fait imprimer des codes QR sur certains emballages de ces produits. En les scannant, les consommateurs peuvent accéder à une vidéo de recette éducative. Il existe également toute une série de programmes de formation au fait maison pour les familles organisés par Angel Yeast dans le monde entier, visant tous à créer des opportunités pour les familles de passer plus de temps ensemble.

En outre, Angel Yeast a intensifié ses efforts en matière d’innovation de produits afin d’offrir davantage d’options de régimes alimentaires nutritifs aux familles. Les lignes de produits comprennent :

  • Boulangerie : Angel Yeast a développé une gamme de préparations pour faire du pain et de gâteaux sains et nutritifs. En outre, ses agents de levage sans aluminium sont largement utilisés en Chine.
  • Arôme YE (extrait de levure) : L’arôme YE est un arôme naturel qui peut sublimer les saveurs et réduire la consommation de sels. Grâce aux efforts d’Angel Yeast, 90 % des sauces soja à teneur réduite en sel en Chine contiennent de l’extrait de levure.
  • Santé : La levure contient des substances nutritives pour les êtres humains. Angel Yeast a innové la technologie des protéines de levure pour produire des produits de soins de santé, médicaux et cosmétiques.
  • Brassage et distillation à domicile : Une autre ligne de produits clés d’Angel Yeast comprend des produits de levure pour la fabrication de bière, de vin et de baijiu (alcool de riz) à domicile et la distillation.

À propos d’Angel Yeast

Fondée en 1986, Angel Yeast Co., Ltd est spécialisée dans la production de levure et de dérivés de levure. Sa gamme de produits comprend la levure et les ingrédients boulangers, les dim sum et les assaisonnements chinois, les extraits de levure salée, les spiritueux distillés et les biocarburants, les enzymes, et des solutions pour la santé humaine, la nutrition animale, la nutrition végétale, et la nutrition microbienne. À l’heure actuelle, Angel Yeast dispose de 12 bases de production avancées internationales en Chine, en Égypte et en Russie, et fournit des produits et services à plus de 160 pays et régions du monde entier.

Photo – https://mma.prnewswire.com/media/1817357/image.jpg

Logo – https://mma.prnewswire.com/media/1586948/angel_logo_Logo.jpg

Posted on

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease

WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001.

“The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the treatment paradigm for TED patients in China.”

ZB001 is a differentiated humanized monoclonal antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment of TED. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye, which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids.

Zenas BioPharma licensed the exclusive rights to develop, manufacture and commercialize ZB001 (Viridian VRDN-001) and other compounds targeting IGF-1R in non-oncology indications in the greater area of China from Viridian Therapeutics, Inc. (Viridian) in October 2020. In October 2021, Viridian submitted an IND for VRDN-001 to the U.S. Food and Drug Administration and in December 2021 initiated a Phase 1/2 clinical trial to evaluate proof of concept in TED patients in North America.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company based in the USA and China committed to becoming a leader in the development and commercialization of immune-based therapies for patients in the US, China and around the world. Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Posted on

Zenas BioPharma soumet une demande en Chine pour un nouveau médicament expérimental pour ZB001 portant sur le traitement de l’ophtalmopathie thyroïdienne

WALTHAM, Massachusetts et SHANGHAI, Chine, 16 mai 2022 (GLOBE NEWSWIRE) — Zenas BioPharma, une société biopharmaceutique mondiale déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients dans le besoin dans le monde entier, a annoncé aujourd’hui la soumission d’une demande pour un nouveau médicament expérimental (IND) à la China National Medical Products Administration (NMPA ou Administration nationale des produits médicaux de la Chine) pour le lancement d’une étude clinique de phase 1/2 sur ZB001 portant sur le traitement de l’ophtalmopathie thyroïdienne (TED). Cette étude vise à évaluer l’innocuité, la tolérance, la pharmacocinétique et l’efficacité préliminaire de ZB001.

« La soumission de l’IND auprès de la NMPA pour pour ZB001 marque une étape importante pour Zenas », a déclaré Hua Mu, MD, PhD, président-directeur général de Zenas. « Il n’existe actuellement aucun traitement approuvé pour les patients atteints de TED en Chine. Les options de traitement sont limitées et impliquent souvent des doses élevées de stéroïdes associées à des effets secondaires graves ou à une intervention chirurgicale. ZB001 a le potentiel de changer le paradigme de traitement pour les patients atteints de TED en Chine. »

ZB001 est un anticorps monoclonal humanisé différencié ciblant le récepteur du facteur de croissance analogue à l’insuline 1 (IGF-1R) pour le traitement de la TED. La TED est une maladie auto-immune invalidante qui provoque une inflammation et une fibrose dans l’orbite de l’œil, ce qui peut causer une vision double, des douleurs et une cécité potentielle. Les patients gravement atteints ont souvent besoin de plusieurs interventions chirurgicales correctives sur l’orbite, les muscles oculaires et les sourcils.

En octobre 2020, Zenas BioPharma a acquis auprès de Viridian Therapeutics, Inc. (Viridian) les droits exclusifs de développement, de fabrication et de commercialisation de ZB001 et d’autres composés ciblant l’IGF-1R dans les indications non oncologiques dans la Grande Chine. En novembre 2021, Viridian a déposé une demande d’IND pour ZB001 (appelé VRDN-001 par Viridian) auprès de la Food and Drug Administration des États-Unis et a lancé en décembre 2021 un essai clinique de phase 1/2 visant à évaluer la preuve de concept chez les patients atteints de TED aux États-Unis.

À propos de Zenas BioPharma

Zenas BioPharma est une société biopharmaceutique mondiale basée en Chine et aux États-Unis déterminée à devenir un leader dans le développement et la commercialisation de traitements immunitaires pour les patients aux États-Unis, en Chine et dans le monde entier. Zenas fait rapidement progresser un vaste pipeline de traitements innovants qui continue de s’accroître grâce à notre stratégie de développement commercial fructueuse. Notre équipe de direction expérimentée et notre réseau de partenaires commerciaux stimulent l’excellence opérationnelle pour apporter des thérapies potentiellement transformatrices afin d’améliorer la vie des personnes confrontées à des maladies rares et auto-immunes. Pour tout complément d’information sur Zenas BioPharma, veuillez consulter le site www.zenasbio.com et nous suivre sur Twitter à l’adresse @ZenasBioPharma et LinkedIn.

Contact auprès des investisseurs et des médias :
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

Posted on

Zenas BioPharma solicita aprovação do medicamento investigacional ZB001 na China para o tratamento de Doença Ocular da Tireoide

WALTHAM, Mass. e XANGAI, China, May 15, 2022 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se tornar líder no desenvolvimento e comercialização de terapias imunológicas para pacientes necessitados em todo o mundo, anunciou hoje que solicitou a aprovação de um novo investigacional (IND) à Administração Nacional de Produtos Médicos da China (NMPA) para o início de um estudo clínico de Fase 1/2 do ZB001 para o tratamento da Doença Ocular da Tireoide (TED). Este estudo foi projetado para avaliar a segurança, tolerabilidade, farmacocinética e eficácia preliminar do ZB001.

“A solicitação de aprovação do ZB001 IND ao NMPA é um marco significativo para a Zenas”, disse Hua Mu, MD, PhD, Diretor Executivo da Zenas. “No momento não existe nenhuma terapia aprovada para pacientes com TED na China. As opções de tratamento são limitadas e muitas vezes envolvem altas doses de esteroides que resultam em efeitos colaterais graves ou intervenção cirúrgica. O ZB001 tem o potencial de mudar o paradigma do tratamento para pacientes com TED na China.”

O ZB001 é um anticorpo monoclonal humanizado diferenciado que direciona o receptor de fator de crescimento semelhante à insulina 1 (IGF-1R) para o tratamento de TED. TED é uma doença autoimune debilitante que causa inflamação e fibrose dentro da órbita do olho, podendo causar visão dupla, dor e cegueira em potencial. Pacientes com doença grave muitas vezes requerem múltiplas cirurgias corretivas da órbita, músculos dos olhos e pálpebras.

A Zenas BioPharma licenciou os direitos exclusivos para desenvolver, fabricar e comercializar o ZB001 e outros compostos direcionados ao IGF-1R em indicações não oncológicas na Grande China da Viridian Therapeutics, Inc. (Viridian) em outubro de 2020. Em novembro de 2021, a Viridian solicitou um IND para o ZB001 (VRDN-001 na Viridian) à Food and Drug Administration dos EUA e, em dezembro de 2021, deu início a um ensaio clínico de Fase 1/2 para avaliar a prova de conceito em pacientes com TED nos EUA.

Sobre a Zenas BioPharma

A Zenas BioPharma é uma empresa biofarmacêutica mundial com sedes nos EUA e na China, comprometida em se tornar líder global no desenvolvimento e comercialização de terapias imunológicas para pacientes nos EUA, China e em todo o mundo. A Zenas está avançando rapidamente um vasto pipeline de terapêuticas inovadoras que continua a crescer por meio da nossa estratégia de desenvolvimento de negócios de sucesso. Nossa experiente equipe de liderança e rede de parceiros de negócios impulsionam a excelência operacional para oferecer terapias potencialmente transformadoras para melhorar a vida das pessoas que enfrentam doenças autoimunes e raras. Para mais informação sobre a Zenas BioPharma, visite www.zenasbio.com siga-nos no Twitter em @ZenasBioPharma e LinkedIn.

Contato com Investidores e com a Mídia:
Joe Farmer
Zenas BioPharma
IR@zenasbio.com

 

Posted on

EU Cuts Eurozone Growth Forecast As Ukraine War Bites

The European Commission on Monday sharply cut its eurozone growth forecast for 2022 to 2.7 percent, blaming skyrocketing energy prices caused by Russia’s invasion of Ukraine.

The war also spurred the EU’s executive to revisit its eurozone inflation prediction for 2022, with consumer prices forecast to jump by 6.1 percent year-on-year, much higher than the earlier forecast of 3.5 percent.

“There is no doubt that the EU economy is going through a challenging period due to Russia’s war against Ukraine, and we have downgraded our forecast accordingly,” EU executive vice president Valdis Dombrovskis said.

“The overwhelming negative factor is the surge in energy prices, driving inflation to record highs and putting a strain on European businesses and households,” he added.

The EU warned that the course of the war was highly uncertain and that the risk of stagflation -– punishing inflation with little or no growth — remained a real risk going forward.

If Russia, the EU’s main energy supplier, should cut off its oil and gas supply to Europe completely, the commission warned that the forecast would worsen considerably.

“Our forecast is subjected to very high uncertainty and risks,” EU commissioner Paolo Gentiloni told reporters.

“Other scenarios are possible under which growth may be lower and inflation higher than we are projecting today. In any case, our economy is still far from a normal situation,” he said.

For the EU as a whole, including the eight countries that do not use the euro as their currency, the commission had also forecast growth of four percent in February, but has now cut this to 2.7 percent, the same level as for the eurozone.

The sharp reduction in expectations is in line with the forecast made in mid-April by the International Monetary Fund, which predicted 2.8 percent growth for the eurozone this year.

The EU’s warning for the months ahead lands as the European Central Bank is increasingly expected to increase interest rates in July to tackle soaring inflation.

Critics warn that this could put a brake on economic activity just when the economy faced the headwinds from the war in Ukraine.

Source: Voice of America

Posted on

Convicted Killer Turned Tech Whiz Confronts His Sordid Past

When he was 20 years old, Harel Hershtik planned and executed a murder, a crime that a quarter of a century later is still widely remembered for its grisly details.

Today, he is the brains behind an Israeli health-tech startup, poised to make millions of dollars with the backing of prominent public figures and deep-pocket investors.

With his company set to go public, Hershtik’s past is coming under new scrutiny, raising questions about whether someone who took a person’s life deserves to rehabilitate his own to such an extent.

“When I was young, I would say that I was stupid and arrogant,” said Hershtik, now 46. “You can be a genius and yet still be very stupid and the two don’t contradict each other.”

Today, Hershtik is the vice president of strategy and technology at Scentech Medical, a company he founded in 2018, while behind bars, which says its product can detect certain diseases through a breath test.

In a three-hour interview with The Associated Press, he repeatedly expressed remorse for his crime.

Hershtik was convicted of murdering Yaakov Sela, a charismatic snake trapper he met when he was 14. The two had a bumpy relationship.

Sela was known for having numerous girlfriends at once, one being Hershtik’s mother. Hershtik said he felt uneasy with how Sela treated some of the women, including his mother.

In early 1996, Sela discovered that Hershtik had stolen 49,000 shekels (about $15,000 at the time) from him, and the two agreed that instead of involving the police, Hershtik would pay him back double that amount. Court documents say Hershtik instead planned to murder Sela.

Pulled over during a drive to gather the money, an accomplice of Hershtik’s fired three shots at Sela, using Hershtik’s mother’s pistol. He then handed Hershtik the gun, according to the documents, and Hershtik shot Sela in the head at close range.

The pair shoved Sela’s body into the trunk and buried it in a grove in the Golan Heights, according to the documents. Weeks later, hikers saw a hand poking up from the earth, and Sela’s body was found.

The sensational crime gripped the nation.

In court documents, prosecutors say Hershtik lied repeatedly in his attempt to distance himself from the murder.

Hershtik said he was compelled to lie so that he could protect the others involved in the scheme, which included his mother.

Hershtik was sentenced to life in prison for premeditated murder and obstructing justice, among other crimes.

He would serve 25 years, during which time Hershtik earned two doctorates, in math and chemistry, and got married three separate times. He said he established 31 companies, selling six of them.

But prison was also a fraught time for Hershtik. He said he spent 11 years in quarantine because of health issues. He was punished twice for setting up internet access to his cell, in one case building a modem out of two dismantled DVD players.

Last year, a parole board determined he had been rehabilitated and no longer posed a danger to society.

As part of his early release and until 2026, he is under nightly house arrest from 11 p.m. to 6 a.m. He must wear a tracking device around his ankle at all times and is barred from leaving the country.

A free man, Hershtik sat recently with the AP in his office in the central city of Rehovot, Israel.

His start-up is waiting for regulatory approval to merge with a company called NextGen Biomed, which trades on the Tel Aviv Stock Exchange and would make Scentech public.

Hershtik said the company’s product is being finalized for detecting COVID-19 through a patient’s breath, and it is working to add other diseases such as certain cancers as well as depression. The product is meant to provide on-the-spot results in a non-invasive way.

The company has received a patent for its technology in Israel and said it is preparing to apply for FDA approval soon.

Hershtik said the merger values the company at around $250 million and that he has raised more than $25 million in funding over the last two years through private Israeli investors. A large part of the investment is from Hershtik’s own money, although he won’t say how much. Prisoners in Israel aren’t barred from doing business, but

Hershtik’s success is rare.

His company is backed by prominent Israeli names, including Yaakov Amidror, who chairs NextGen and is a former chief of the country’s National Security Council.

“According to the rules of the country, the man is allowed to rehabilitate. He paid his price and he rehabilitated. So there is no reason not to help him rehabilitate,” Amidror, who testified to the parole board on Hershtik’s behalf, told the AP.

But Hershtik’s past is already haunting him. Hershtik was demoted from CTO earlier this year to his current position, in part because he didn’t want his crime to scare away investors.

“Harel has always said if for some reason his presence is a problem and the company would be better off without him, that he’s willing to leave the company,” said Drew Morris, a board member and investor.

As Scentech seeks to take its product to market, investors will need to decide whether Hershtik’s rap sheet influences where they put their money.

Ishak Saporta, a senior lecturer at Tel Aviv University’s Coller School of Management, said he believed investors would be drawn to the company’s potential for profit rather than deterred by Hershtik’s history.

“What concerns me here is that he became a millionaire. He paid his debt to society in jail. But does he have a commitment to the victim’s family,” Saporta asked.

Tovia Bat-Leah, who had a child with Sela, suggested he help fund her daughter’s education or create a reptile museum in Sela’s name.

“He served his time but he should also make some kind of reparation,” she said.

Hershtik sees the good that could come about from the company as the ultimate form of repentance. He said he could have used his smarts to create any sort of company with no benefit to society but chose health tech instead.

“Trust me, this is not for the money,” he said.

Source: Voice of America